MARKET

MEDP

MEDP

Medpace Holdings
NASDAQ
404.15
+0.88
+0.22%
After Hours: 404.15 0 0.00% 16:02 03/28 EDT
OPEN
403.42
PREV CLOSE
403.27
HIGH
407.14
LOW
401.76
VOLUME
169.48K
TURNOVER
0
52 WEEK HIGH
419.42
52 WEEK LOW
179.49
MARKET CAP
12.43B
P/E (TTM)
45.53
1D
5D
1M
3M
1Y
5Y
Sharecare, Inc. (SHCR) Reports Q4 Loss, Lags Revenue Estimates
NASDAQ · 7h ago
Press Release: Medpace Holdings, Inc. to Report First Quarter 2024 Financial Results on April 22, 2024
Medpace Holdings, Inc. To Report First Quarter 2024 Financial Results on April 22, 2024. The Company will host a conference call the following morning, April 23, 2024, at 9:00 a.m. ET to discuss these results. Medpace will report its first quarter 2024 financial results after the market close on Monday, April 22.
Dow Jones · 8h ago
Reasons to Add Cencora (COR) Stock in Your Portfolio Now
NASDAQ · 1d ago
Medpace Holdings (NASDAQ:MEDP) stock performs better than its underlying earnings growth over last five years
Medpace Holdings, Inc. Shares have gained 564% in the last five years. The company has managed to grow its earnings per share at 35% a year. Medpace Holdings has a total shareholder return of 122% over the last 12 months. It's worth looking at the company's earnings growth over the longer term.
Simply Wall St · 1d ago
Weekly Report: what happened at MEDP last week (0318-0322)?
Weekly Report · 3d ago
U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies -- Heard on the Street
Congress is considering a bill to blacklist certain Chinese biotech companies. U.S. Companies have outsourced contract manufacturing and research to Chinese companies. The bill could have unintended consequences for companies that rely on those companies for drug development. Congress is considering the legislation to protect national-security concerns.
The Wall Street Journal · 5d ago
Medpace Holdings: Statement of changes in beneficial ownership of securities
Press release · 03/18 21:42
Medpace Holdings Price Target Announced at $395.00/Share by Deutsche Bank
Dow Jones · 03/18 12:27
More
About MEDP
Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.

Webull offers Medpace Holdings Inc stock information, including NASDAQ: MEDP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MEDP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MEDP stock methods without spending real money on the virtual paper trading platform.